Fecal calprotectin concentration in patients with colorectal carcinoma

Kristinsson, Jon; Røseth, Arne; Fagerhol, Magne K.; Aadland, E; Schjønsby, H; Børmer, Ole P.; Raknerud, N; Nygaard, K

doi:10.1007/bf02237485

Cited by 81 publications

(59 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…30) In contrast, no substantial increase was observed in osteoarthritis. 30) An increase in blood calprotectin concentration was also reported in patients with Crohn's disease, 34) colorectal carcinoma, 35) cystic fibrosis, 36,37) multiple sclerosis, 38) human immunodeficiency virus (HIV) infection, 39) and patients who had undergone major surgery. 42) A more intense increase in calprotectin concentration has been observed in body fluid from local inflammatory sites than in blood.…”

Section: Pathological States In Which Calpro-tectin Is Upregulatedmentioning

confidence: 90%

“…11,[29][30][31][32][33][34][35][36][37][38][39][40][41] Examples of the inflammatory states in which extracellular calprotectin reportedly increases are depicted in Table 1. The calprotectin-upregulated pathological states were also listed in more detail in a review by Johne et al 21) Berntzen et al reported that in healthy human serum/ plasma, the concentration of calprotectin was less than 1 mg/ml, while the plasma concentration of patients with rheumatoid arthritis (RA) was reportedly increased to approximately 10-fold higher concentrations as mean values.…”

Section: Pathological States In Which Calpro-tectin Is Upregulatedmentioning

confidence: 99%

See 1 more Smart Citation

Calprotectin (S100A8/S100A9), an Inflammatory Protein Complex from Neutrophils with a Broad Apoptosis-Inducing Activity

Yui

Nakatani

Mikami

2003

Biological & Pharmaceutical Bulletin

283

211

View full text Add to dashboard Cite

Calprotectin, a complex of two calcium-binding proteins that belong to the S100 protein family, is abundant in the cytosolic fraction of neutrophils. A high level of calprotectin reportedly exists in extracellular fluid during various inflammatory conditions, such as rheumatoid arthritis, cystic fibrosis and abscesses. However, the exact biological role(s) of the factor is now under investigation. We recently observed that neutrophils contain a factor that shows growth-inhibitory and apoptosis-inducing activities against various cell types including tumor cells and normal fibroblasts, and we identified that factor as calprotectin. The findings suggest that calprotectin exerts a regulatory activity in inflammatory processes through its effect on the survival or growth states of cells participating in the inflammatory reaction. It is also possible that calprotectin, at a high concentration, might have a deleterious effect on fibroblasts and influence the recovery of inflammatory tissue. Therefore, the protein factor may be a new drug target to control inflammatory reactions. We found that a few of the Amaryllidaceae alkaloids effectively inhibited the growth-inhibitory and apoptosis-inducing activities of calprotectin. In this article, we focus on the biological functions of calprotectin in extracellular fluids, focusing on its apoptosis-inducing activity.

show abstract

Section: Pathological States In Which Calpro-tectin Is Upregulatedmentioning

confidence: 90%

Section: Pathological States In Which Calpro-tectin Is Upregulatedmentioning

confidence: 99%

Calprotectin (S100A8/S100A9), an Inflammatory Protein Complex from Neutrophils with a Broad Apoptosis-Inducing Activity

Yui

Nakatani

Mikami

2003

Biological & Pharmaceutical Bulletin

283

211

View full text Add to dashboard Cite

show abstract

“…A second portion of the feces was homogenized according to a simplified method by Roche and assayed for calprotectin. Calprotectin was quantified by an ELISA as described previously [20]. The reference concentrations for calprotectin in plasma were (mean9/2SD) 0.32 Á1.97 mg/l.…”

Section: Inflammatory Markers Calprotectin S100a12 and Lactoferrinmentioning

confidence: 99%

Time patterns of changes in biomarkers, symptoms and histopathology during pelvic radiotherapy

Larsen

Bjørge²,

Klementsen³

et al. 2007

Acta Oncologica

View full text Add to dashboard Cite

“…Fish oil with long chain n-3 fatty acids (Paulsen et al, 1998;Bartsch et al, 1999;Stark et al, 2000) 3) Colonic inflammation/faecal calprotectin (Kristinsson et al, 1998;Kronborg et al, 2000) Diets deficient in calcium lead to an exposure of the colon to free bile and fatty acids, and to an inflammatory response (Wargovich et al, 1983;Newmark et al, 1984). The colonic inflammation increases initiation and promotion of colon cancer (Gillen et al, 1994;Biasco et al, 1995;Kristinsson et al, 1999;Okayasu et al, 2002).…”

Section: Study Protocolmentioning

confidence: 99%

A pilot randomised controlled trial to reduce colorectal cancer risk markers associated with B-vitamin deficiency, insulin resistance and colonic inflammation

Cirocco

Giacca

et al. 2005

Br J Cancer

View full text Add to dashboard Cite

Colorectal cancer risk is associated with biochemical markers for B-vitamin deficiency, insulin resistance and colonic inflammation, suggesting that these three conditions are each involved in colon carcinogenesis. We expected that dietary supplements of folic acid, n-3 fatty acids and calcium would reduce the markers and thus possibly cancer risk. We therefore randomised 98 participants, with previous colonic polyps or intramucosal carcinomas, to a combined treatment of supplementary folic acid, fish oil and calcium carbonate, or placebos for 28 days. Blood and faecal samples were obtained prior to and at the conclusion of the intervention and analysed for plasma folate, homocysteine, insulin, free fatty acids, triglycerides and faecal calprotectin. In addition, plasma vitamin B 12 , thiamin, glucose and C-reactive protein were assessed. Our supplemental strategy modestly affected some of the biomarkers associated with folate metabolism and insulin resistance, but had no effect on those associated with colonic inflammation. This pilot study demonstrates the feasibility and practicality of clinical trials aimed at reducing diet-related biochemical risk markers for colon cancer. We suggest that long-term intervention studies with tumour-related end points should be undertaken when the intervention agents used are found effective in short-term biochemical risk marker trials.

show abstract

Fecal calprotectin concentration in patients with colorectal carcinoma

Cited by 81 publications

References 18 publications

Calprotectin (S100A8/S100A9), an Inflammatory Protein Complex from Neutrophils with a Broad Apoptosis-Inducing Activity

Calprotectin (S100A8/S100A9), an Inflammatory Protein Complex from Neutrophils with a Broad Apoptosis-Inducing Activity

Time patterns of changes in biomarkers, symptoms and histopathology during pelvic radiotherapy

A pilot randomised controlled trial to reduce colorectal cancer risk markers associated with B-vitamin deficiency, insulin resistance and colonic inflammation

Contact Info

Product

Resources

About